Kim Hyeon Chang, Lee Hokyou, Lee Hyeok-Hee, Seo Eunsun, Kim Eunji, Han Jiyen, Kwon Ja-Young
Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Clin Hypertens. 2022 Jan 3;28(1):1. doi: 10.1186/s40885-021-00188-w.
The Korean Society of Hypertension has published the Korea Hypertension Fact Sheet 2021 to provide an overview of the magnitude and management status of hypertension and their recent trends.
The Fact Sheets were based on the analyses of Korean adults aged 20 years or older of the 1998-2019 Korea National Health and Nutrition Examination Survey and the 2002-2019 National Health Insurance Big Data.
Currently, the population average of systolic/diastolic blood pressure was 119/76 mmHg in Korean adults aged 20 years or older showing little change in the recent decade. It is estimated that 28% of the adult population aged 20 or older (33% of adults aged 30 or older) have hypertension. The estimated number of people with hypertension was 6.30 million for men and 5.77 million for women, and 1.96 million for men and 2.99 million for women among the population aged 65 or older. The number of people diagnosed with hypertension increased from 3.0 million in 2002 to 10.1 million in 2019. During the same period, the number of people using antihypertensive medication increased from 2.5 million to 9.5 million, and the number of people adherent to treatment increased from 0.6 million to 6.9 million. Among antihypertensive prescriptions, 40.6% of the patients received monotherapy, 43.4% received dual therapy, and 16.0% received triple or more therapy. The most commonly prescribed antihypertensive medication was angiotensin receptor blockers (ARB), followed by calcium channel blockers (CCB) and diuretics. In young women, angiotensin-converting enzyme inhibitors (ACEi), ARB and CCB are less frequently prescribed than in men, but 59.5% of hypertensive women aged 20-39 are prescribed ACEi or ARBs. Hypertensive disorders during pregnancy have been increasing over the past 10 years. In 2019, 5.4% of women who gave birth were diagnosed with chronic hypertension and 3.1% with pregnancy-induced hypertension.
To achieve further improvement in management of hypertension, we need to encourage awareness and treatment in young adults. It is required to develop tailored prevention and management strategies that are appropriate for and inclusive of various demographics.
韩国高血压学会发布了《2021年韩国高血压情况说明书》，以概述高血压的严重程度、管理状况及其近期趋势。
这些情况说明书基于对1998 - 2019年韩国国家健康与营养检查调查中20岁及以上韩国成年人以及2002 - 2019年国家健康保险大数据的分析。
目前，20岁及以上韩国成年人的收缩压/舒张压人口平均值为119/76 mmHg，近十年来变化不大。据估计，20岁及以上成年人口中有28%（30岁及以上成年人中有33%）患有高血压。高血压患者估计人数男性为630万，女性为577万；65岁及以上人群中，男性为196万，女性为299万。被诊断为高血压的人数从2002年的300万增加到2019年的1010万。在此期间，使用抗高血压药物的人数从250万增加到950万，坚持治疗的人数从60万增加到690万。在抗高血压处方中，40.6%的患者接受单药治疗，43.4%接受联合治疗，16.0%接受三联或更多药物治疗。最常用的抗高血压药物是血管紧张素受体阻滞剂（ARB），其次是钙通道阻滞剂（CCB）和利尿剂。在年轻女性中，血管紧张素转换酶抑制剂（ACEi）、ARB和CCB的处方频率低于男性，但20 - 39岁的高血压女性中有59.5%被处方使用ACEi或ARB。过去10年中，妊娠期高血压疾病一直在增加。2019年，5.4%的分娩女性被诊断为慢性高血压，3.1%被诊断为妊娠期高血压。
为了进一步改善高血压管理，我们需要鼓励年轻人提高认识并接受治疗。需要制定适合并涵盖不同人群的针对性预防和管理策略。
